![](/img/cover-not-exists.png)
PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL
M Mason, N Freemantle, A Parnaby, D HögbergVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71914-3
File:
PDF, 75 KB
english, 2010